Pulmonary vascular diseases

State of the art session
Chairs: A. Vonk Noordegraaf (Amsterdam, Netherlands), S. Ulrich (Zurich, Switzerland)
Aims: to summarise the vast progress that has been made in understanding and treatment of pulmonary hypertension related to underlying lung disease in recent years; to discuss the biology and epigenetic causes of pulmonary hypertension, and how this information may help to develop novel treatments; to provide an update about recent trials in pulmonary hypertension; to provide novel insights into the pulmonary vascular nature of low DLCO-related pulmonary hypertension.

The origin and consequence of pulmonary hypertension in patients with lung-related disease J. Barberà Mir (Barcelona, Spain)
Pulmonary hypertension in patients with autoimmune disease M. Humbert (Le Kremlin-Bicêtre, France)
Failures and successes in treatment of pulmonary hypertension in patients with interstitial lung disease: past, present and future A. Waxman (Boston, United States)
Low DLCO in patients with pulmonary arterial hypertension: a different vascular phenotype? E. Nossent (Amsterdam, Netherlands)
Discussion and Q&A